ArticleJournal of neuro-oncology2020
Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas.
Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma.Tomography (Ann Arbor, Mich.) · 2023Trial
- Percentage of signal recovery (PSR): a more accurate marker than rCBV for differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiosurgery.Journal of neuro-oncology · 2025Article
- A self-supervised multimodal deep learning approach to differentiate post-radiotherapy progression from pseudoprogression in glioblastoma.Scientific reports · 2025Article
- Standardized reporting systems for (which?) brain tumors from in the dark: cons of the BT-RADS.European radiology · 2024Article
- Brain Tumor-Radiology and Data System (BT-RADS)-an imperfect system but a worthwhile start.European radiology · 2024Article
- Interrater Agreement of BT-RADS for Evaluation of Follow-up MRI in Patients with Treated Primary Brain Tumor.AJNR. American journal of neuroradiology · 2024Article
- Pre-operative spinal cord perfusion quantified by DSC MRI as a predictor of post-operative prognosis in patients with cervical spondylotic myelopathy.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2024Article
- Validating Brain Tumor Reporting and Data System (BT-RADS) as a Diagnostic Tool for Glioma Follow-Up after Surgery.Biomedicines · 2024Article
- Arterial Spin-Labeling and DSC Perfusion Metrics Improve Agreement in Neuroradiologists' Clinical Interpretations of Posttreatment High-Grade Glioma Surveillance MR Imaging-An Institutional Experience.AJNR. American journal of neuroradiology · 2024Article
- Using Brain Tumor MRI Structured Reporting to Quantify the Impact of Imaging on Brain Tumor Boards.Tomography (Ann Arbor, Mich.) · 2023Article
- Challenges and opportunities for advanced neuroimaging of glioblastoma.The British journal of radiology · 2023Review
- Diffusion imaging could aid to differentiate between glioma progression and treatment-related abnormalities: a meta-analysis.Insights into imaging · 2022Review
- Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.Journal of oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Brain Tumor Reporting and Data System (BT-RADS) category 3 is suitable for identifying cases with intermediate probability of tumor recurrence that do not meet the Response Assessment in Neuro-Oncology (RANO) criteria for progression. The aim of this study was to evaluate the added value of dynamic susceptibility contrast-enhanced perfusion-weighted imaging (DSC PWI) and diffusion-weighted imaging (DWI) to BT-RADS for differentiating tumor recurrence from non-recurrence in postoperative high-grade glioma (HGG) patients with category 3 lesions.
methodsPatients with BT-RADS category 3 lesions were included. The maximal relative cerebral blood volume (rCBV
resultsFifty-one of 91 patients had tumor recurrence, and 40 patients did not. There were significant differences in rCBV
conclusionAdding DSC PWI and DWI to BT-RADS can significantly improve the diagnostic performance for differentiating tumor recurrence from non-recurrence in BT-RADS category 3 lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.